<DOC>
	<DOCNO>NCT00000965</DOCNO>
	<brief_summary>To define pharmacokinetic parameter ( blood level ) total phosphorylated zidovudine ( AZT ) peripheral blood mononuclear cell ( PBMC ) HIV-infected patient . Despite understanding serum ( plasma ) pharmacokinetics ( blood level ) AZT , therapeutic concentration range optimal dosing interval yet determine .</brief_summary>
	<brief_title>The Effects Zidovudine Blood HIV-Infected Patients</brief_title>
	<detailed_description>Despite understanding serum ( plasma ) pharmacokinetics ( blood level ) AZT , therapeutic concentration range optimal dosing interval yet determine . Three study plan two separate patient group . Group ( 1 ) Patients never take AZT start standard dose AZT . Blood sample take hourly 8-hour period day 1 14 . Other blood sample take day 2 , 4 , 8 . Group ( 2 ) Patients never take AZT give standard dose first week , increase week week 5 . Blood sample take end weekly treatment . After 4 week standard treatment , patient group 1 2 return receive single morning dose oral AZT . Blood sample take immediately dose 1 , 2 , 4 , 6 , 8 hour dose . After 48-hour clearance period , patient return resume dose . Blood sample take 8-hour period . After 24 week standard treatment , pharmacokinetic study repeat .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : FDAapproved antipneumocystis antifungal prophylactic suppressive regimen . Acyclovir 3 week intermittently . Patients must : Meet current guideline receive prescription zidovudine . Have write informed consent subject parent guardian 18 . Be capable understand give informed consent . Women minorities actively encourage participate . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Malabsorption syndrome ( 3 loose stools/day least 4 week associate unintentional weight loss great 10 percent body weight ) . Concurrent Medication : Excluded : Probenecid nonFDA approve investigational drug . Systemic chemotherapy . Other antiviral agent , license investigational , include ganciclovir , foscarnet , ribavirin , didanosine ( ddI ) , dideoxycytidine ( ddC ) , dideoxydidehydrothymidine ( D4T ) . Chronic acyclovir . Patients follow exclude : Active bacterial , fungal , viral infection require systemic therapy specifically allow . Significant , chronic medical condition could impair compliance study treatment . Prior Medication : Excluded : Zidovudine ( AZT ) . Systemic chemotherapy within previous 6 month . Acyclovir within 30 day study entry . Risk Behavior : Excluded : Unable take oral medication reliably . Alcohol drug abuse could impair compliance study treatment .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Leukocytes , Mononuclear</keyword>
	<keyword>Drug Evaluation</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>Phosphorylation</keyword>
</DOC>